MnO nanoparticles with unique excitation-dependent fluorescence for multicolor cellular imaging and MR imaging of brain glioma

Lai, Junxin; Wang, Tingjian; Wang, Hao; Shi, Fengqiang; Gu, Wei; Ye, Ling

doi:10.1007/s00604-018-2779-5

Cited by 22 publications

(11 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Size is an important factor, as it affects the tumbling relaxation rates, with larger CAs typically displaying larger r 1 , as is seen here. However, the few reported high-field r 2 /r 1 ratios are similar (7.0−11), 41,49,50 compared to 9 for MnO pyrr , with 6.7 nm MnO-TETT 46 standing out with an r 2 /r 1 of 3 at 7 T. Similarly sized instances are easier to find at lower fields, where MnO pyrr sits somewhat in the middle range. For example, our r 1 is significantly higher than that for 7 nm MnO-oleate-PEGP 44 (by almost an order of magnitude); however the r 1 for D-glucuronic-acid-coated 2.5 nm MnO NPs is almost 2.5 times higher compared to our system.…”

Section: Relaxometry Of Mno Pyrrcontrasting

confidence: 76%

Bifunctional Pyrrolidin-2-one Terminated Manganese Oxide Nanoparticles for Combined Magnetic Resonance and Fluorescence Imaging

Banerjee

Bertolesi

Ling

et al. 2019

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Multimodal probes are an asset for simplified, improved medical imaging. In particular, fluorescence and magnetic resonance imaging (MRI) are sought-after combined capabilities. Here, we show that pyrrolidin-2-one-capped manganese oxide nanoparticles (MnO pyrr NPs) combine MRI with fluorescence microscopy to function as efficient bifunctional bio-nanoprobes. We employ a one-pot synthesis for ca. 10 nm MnO NPs, wherein manganese(II) 2,4-pentadionate is thermally decomposed using pyrrolidin-2-one as a solvent and capping ligand. The MnO pyrr NPs are soluble in water without any further postsynthetic modifications. The r 1 relaxivity and r 2 /r 1 ratio indicate that these NPs are potential T 1 MRI contrast agents at clinical (3 T) and ultrahigh (9.4 T) magnetic fields. Serendipitously, the as-prepared NPs are photoluminescent. The unexpected luminescence is ascribed to the modification of the pyrrolidin-2-one during the thermal treatment. MnO pyrr NPs are successfully used to enable fluorescence microscopy of HeLa cells, demonstrating bifunctional imaging capabilities. A low cytotoxic response in two distinct cell types (HeLa, HepG2) supports the suitability of MnO pyrr NPs for biological imaging applications.

show abstract

Section: Relaxometry Of Mno Pyrrcontrasting

confidence: 76%

Bifunctional Pyrrolidin-2-one Terminated Manganese Oxide Nanoparticles for Combined Magnetic Resonance and Fluorescence Imaging

Banerjee

Bertolesi

Ling

et al. 2019

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

show abstract

“…Afterwards, the diluted RBC suspension (200 μL) was added to PBS (1 mL) as the negative control, to water as the positive control, and to MnCO 3 @BSA nanoparticles at different Mn concentrations (0–100 μM). 28 After incubation at 37°C for 2 h, the released hemoglobin was obtained by centrifugation at 10,000 r/min for 10 min. Absorbance of the obtained supernatant at 570 nm was observed by photometric analysis.…”

Section: Methodsmentioning

confidence: 99%

Albumin-templated manganese carbonate nanoparticles for precise magnetic resonance imaging of acute myocardial infarction

Han

Wang

et al. 2022

J Biomater Appl

Self Cite

View full text Add to dashboard Cite

Myocardial infarction (MI) is a major cause of death worldwide. Early and precise diagnosis of myocardial viability after MI is extremely important for effective treatment and prognosis evaluation. Herein, we developed the BSA-templated manganese carbonate (MnCO3@BSA) nanoparticles as an MR imaging contrast agent for accurate detection of the infarcted regions. The chemophysical features, targeting capability toward the infarct, and biocompatibility were evaluated. The nanoparticles showed superior chemical stability. In vitro study suggested that the MnCO3@BSA nanoparticles do not enter normal cardiomyocytes. MR imaging indicated that the MnCO3@BSA with a high longitudinal ( r 1) relaxivity of 5.84 mM−1s−1 at physiological condition specifically accumulated into the infarcted regions of myocardial ischemia/reperfusion (I/R) mice. In addition, the MnCO3@BSA nanoparticles exhibited low cytotoxicity to cardiomyocytes, no damage to organs and good hemocompatibility. Thereby, the MnCO3@BSA nanoparticles manifested great potential as an extracellular contrast agent of MR imaging for sensitive and specific detection of the infarcted regions during acute myocardial I/R injury.

show abstract

“…Some methods which do not use fluorescent dye have been introduced. Lai et al found that MnO which has been obtained through the thermal decomposition of an excess of oleic acid (oleic acid: manganese content > 2) displays fluorescence excitation characteristics across its entire visible spectrum 42. To verify its bio-imaging performance, C6 cells were detected following surface modification of TETT, and it was found that cells exhibited blue and green fluorescence at 405 nm and 458 nm, respectively.…”

Section: Mno-based Nanoparticles In Tumor Diagnosis and Therapymentioning

confidence: 99%

<p>Manganese Oxide Nanoparticles As MRI Contrast Agents In Tumor Multimodal Imaging And Therapy</p>

Cai¹,

Zhu²,

Zeng³

et al. 2019

IJN

188

118

View full text Add to dashboard Cite

Contrast agents (CAs) play a crucial role in high-quality magnetic resonance imaging (MRI) applications. At present, as a result of the Gd-based CAs which are associated with renal fibrosis as well as the inherent dark imaging characteristics of superparamagnetic iron oxide nanoparticles, Mn-based CAs which have a good biocompatibility and bright images are considered ideal for MRI. In addition, manganese oxide nanoparticles (MONs, such as MnO, MnO2, Mn3O4, and MnOx) have attracted attention as T1-weighted magnetic resonance CAs due to the short circulation time of Mn(II) ion chelate and the size-controlled circulation time of colloidal nanoparticles. In this review, recent advances in the use of MONs as MRI contrast agents for tumor detection and diagnosis are reported, as are the advances in in vivo toxicity, distribution and tumor microenvironment-responsive enhanced tumor chemotherapy and radiotherapy as well as photothermal and photodynamic therapies.

show abstract

MnO nanoparticles with unique excitation-dependent fluorescence for multicolor cellular imaging and MR imaging of brain glioma

Cited by 22 publications

References 43 publications

Bifunctional Pyrrolidin-2-one Terminated Manganese Oxide Nanoparticles for Combined Magnetic Resonance and Fluorescence Imaging

Bifunctional Pyrrolidin-2-one Terminated Manganese Oxide Nanoparticles for Combined Magnetic Resonance and Fluorescence Imaging

Albumin-templated manganese carbonate nanoparticles for precise magnetic resonance imaging of acute myocardial infarction

<p>Manganese Oxide Nanoparticles As MRI Contrast Agents In Tumor Multimodal Imaging And Therapy</p>

Contact Info

Product

Resources

About